Glaucoma is an asymptomatic eye-related disorder that occurs due to the buildup of fluid pressure inside the eye. This leads to damage of the optic nerve in the eye, and is a hereditary disorder. Immediate treatment of people suffering from glaucoma is essential as glaucoma in severe cases may result in loss of vision permanently. In addition, glaucoma is anticipated to be the leading cause of blindness among people in the age group of 60 years and above. The glaucoma surgeries comprise of non-invasive devices, invasive as well as minimally invasive devices to decrease the production of intraocular fluid, which is also known as aqueous humor. The key factors that drive the market growth include increase in prevalence of glaucoma disease worldwide and growth in geriatric population. In addition, rise in demand for advanced ophthalmic devices supplement the market growth. The global glaucoma surgery devices market was valued at $353 million in 2016, and is expected to reach $2,143 million by 2023, registering a CAGR of 29.3% from 2017 to 2023.
The glaucoma surgery devices market is segmented based on product, surgery type, end user, and region. Based on product, it is divided into glaucoma drainage devices, glaucoma laser devices, and implants & stents. Based on the surgery type, tit is bifurcated into conventional glaucoma surgeries, and minimally invasive glaucoma surgeries. The end users are classified into eye hospitals, ophthalmology clinics, and outpatient surgical centers. The glaucoma drainage devices segment is growing at a fast pace, registering a CAGR of 29.7%. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In addition, glaucoma surgery devices are majorly incorporated in the eye hospitals, and thus this segment is projected to generate the highest revenue throughout the forecast period.
In the recent years, Asia-Pacific has witnessed rapid growth in the glaucoma surgery devices market, owing to steady increase in the prevalence of glaucoma in the Asian population. In addition, rise in the number of people suffering from primary angle-closure glaucoma in Japan, China, and South Korea supplement this growth further.
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Surgery Type
By End User
KEY MARKET PLAYERS
The other players in the value chain include (profiles not included in the report)
Fertility Services Market by Procedure (IVF with ICSI, Surrogacy, IVF without ICSI, IUI, and Others), Service (Fresh Non-Donor, Frozen Non-Donor, Egg and Embryo Banking, Fresh Donor, and Frozen Donor), and End User (Fertility Clinics, Hospitals, Surgical Centers, and Clinical Research Institutes) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Fertility services are treatments, which aid in treating infertility in patients. In vitro fertilization (IVF), surrogacy, artificial insemination, and others are different forms of infertility services, which assists couples with infertility problems, single mothers, and the LGBT community to procreate. The global fertility services market was valued at $16,761 million ...
February 2018 | $5370 |View Details>>
Embolization Particle or embolisation refers to the passage and lodging of an embolus within the bloodstream. It may be pathological (in which sense it is also called embolism), for example a pulmonary embolism, or therapeutic, as a hemostatic treatment for bleeding or as a treatment for some types of cancer ...
February 2018 | $4880 |View Details>>
This report studies the IV Flush Syringe market. Health care professionals use IV flush syringes to clear out patients’ catheters and intravenous lines to ensure the tubes are sterile. Nurse Assist, a Texas-based medical device manufacturer, recalled all of its Normal Saline IV Flush Syringes in 2016 after ...
February 2018 | $4880 |View Details>>
Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have ...
February 2018 | $3480 |View Details>>
UPCOMING MARKET RESEARCH REPORTS
2018 © Copyright Big Market Research